Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

NCT00503841 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

44

Enrollment

OTHER

Sponsor class

Stopped All enrolled participants were screen failures, no data were collected for outcome measures.

Conditions

Breast Cancer

Interventions

DRUG: erlotinib hydrochloride
OTHER: immunohistochemistry staining method
OTHER: laboratory biomarker analysis
PROCEDURE: biopsy
PROCEDURE: conventional surgery
PROCEDURE: neoadjuvant therapy

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]